We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
-1.36%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$28.1M
Cap. Flow
+$31M
Cap. Flow %
23.47%
Top 10 Hldgs %
90.06%
Holding
14
New
1
Increased
5
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
IMTX icon
Immatics
IMTX
+$1.58M
2
BPMC
Blueprint Medicines
BPMC
+$993K
3
BCYC
Bicycle Therapeutics
BCYC
+$582K
4
RGNX icon
Regenxbio
RGNX
+$298K
5
RPTX
Repare Therapeutics
RPTX
+$107K

Top Sells

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$5.3M
2
SLN
Silence Therapeutics
SLN
+$3.4M
3
ARWR icon
Arrowhead Research
ARWR
+$2.75M
4
MRUS
Merus
MRUS
+$1.58M
5
ARVN icon
Arvinas
ARVN
+$1.04M

Sector Composition

Rank Sector Weight
1 Healthcare 67.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
$43M 32.63%
+75,000
New +$41.5M
ARWR icon
2
Arrowhead Research
ARWR
$12.4B
$15.4M 11.69%
795,813
-112,661
-12% -$2.75M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$11.5M 8.74%
124,600
+10,000
+9% +$993K
KYMR icon
4
Kymera Therapeutics
KYMR
$8.94B
$9.88M 7.49%
208,743
-120,000
-37% -$5.3M
RGNX icon
5
Regenxbio
RGNX
$708M
$9.76M 7.4%
930,708
+24,460
+3% +$298K
ARVN icon
6
Arvinas
ARVN
$572M
$9.58M 7.26%
388,766
-40,000
-9% -$1.04M
MRUS
7
DELISTED
Merus
MRUS
$5.89M 4.46%
117,855
-30,254
-20% -$1.58M
SLN
8
Silence Therapeutics
SLN
$564M
$5.77M 4.37%
317,214
-183,000
-37% -$3.4M
BCYC
9
Bicycle Therapeutics
BCYC
$292M
$4.12M 3.12%
181,911
+25,219
+16% +$582K
IMTX icon
10
Immatics
IMTX
$1.32B
$3.81M 2.89%
333,502
+133,502
+67% +$1.58M
ACET icon
11
Adicet Bio
ACET
$74.7M
$3.64M 2.76%
158,200
– –
DTIL icon
12
Precision BioSciences
DTIL
$207M
$3.42M 2.59%
381,803
– –
RPTX
13
DELISTED
Repare Therapeutics
RPTX
$3.4M 2.58%
989,364
+32,432
+3% +$107K
STRO icon
14
Sutro Biopharma
STRO
$421M
$2.64M 2%
76,250
– –

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Aquilo Capital Management held 14 positions worth $132M, up 27% from $104M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Aquilo Capital Management deployed $31M of net new capital in Q3 2024, opening 1 new position and adding to 5 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Kymera Therapeutics, an estimated $5.3M trimmed.

  • Aquilo Capital Management added most to Immatics in Q3 2024, an estimated $1.58M increase.
  • Aquilo Capital Management's biggest Q3 2024 reduction was Kymera Therapeutics, cutting an estimated $5.3M.
  • Aquilo Capital Management's ten largest holdings make up 90% of its $132M portfolio in Q3 2024.
  • Aquilo Capital Management opened 1 new position and closed 0 in Q3 2024.
  • Aquilo Capital Management's portfolio value rose 27% quarter-over-quarter to $132M.

Based on Aquilo Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.